Table 2.
Adverse effects in the included studies according to the formulation of intravenous iron.
| Studies (first author, date of publication) | Iron formulation administered | Adverse events (number of patients) |
| Lee 2018 | FCM and IS | Headache (4, no details for the included group) |
| Jose 2019 | FCM | Injection site reaction (1), elevated serum transaminase level (1), hypophosphatemia (2) |
| IS | Injection site reaction (2), epigastric pain (2), hypophosphatemia (3) | |
| Naqash 2018 | FCM | Headache (1) |
| IS | Nausea and tingling sensation (3), headache (2), arthralgia (1) | |
| Sumathy 2017 | FCM | Nausea, giddiness, arthralgia (total 3) |
| IS | Nausea, vomiting, urticaria (total 7) | |
| Mahey 2016 | FCM | Gastritis (2), itching (2), rash (1), hypophosphatemia (15) |
| IS | Fever (2), gastritis (2), vomiting (2), injection site pain (3), itching (1), hypophosphatemia (12) | |
| Joshi 2016 | FCM | Chest discomfort (2), nausea (1) |
| IS | Injection site reaction, nausea, hypotension (total 6) | |
| Garg 2015 | FCM | Injection site reaction (1), rash (1), headache (3), nausea (1) |
| IS | Injection site reaction (2), rash (2), headache (4), nausea (2) | |
| Hol 2015 | FCM | Rigors (1), headache (2), flushing or skin eruption (1), itching (2), injection site pain or redness (3) |
| IS | Rigors (1), headache (1), itching (3), injection site pain or redness (5), nausea and vomiting (2) | |
| Rathod 2015 | FCM | Arthralgia or tingling sensation (1) |
| IS | Transient hypotension (3), arthralgia or tingling sensation (3) |